Merck to Test Promising HIV Vaccines Using NIAID Network

BETHESDA, Maryland—Merck & Co. will use a worldwide research network organized and funded by the National Institute of Allergy and Infectious Diseases (NIAID) to test promising HIV vaccines it develops.

The agreement will enable Merck to evaluate its vaccines in a collaborative effort with the international HIV Vaccine Trials Network (HVTN), which consists of centers at 12 US academic sites and 13 institutions in Africa, Asia, South America, and the Caribbean.